Suppression of p24 antigen in sera from HIV-infected individuals with low-dose alpha-interferon and zidovudine: a pilot study.
On the basis of the observations that HIV antigenaemia indicates a high risk of progression to AIDS and that zidovudine and alpha-interferon act synergistically against HIV replication in vitro, we performed a pilot trial including 12 HIV-infected asymptomatic patients with detectable p24 antigen in serum. The patients received low-dose lymphoblastoid alpha-interferon alone for 4 weeks followed by a combination of interferon and low-dose zidovudine for a further 16 weeks. The median p24 antigen level decreased significantly (P less than 0.01), the decrease being most pronounced at week 5. Decreases in haemoglobin and neutrophil counts were observed. Four patients required reduction of the zidovudine dose and three patients were transfused. In conclusion, the drug combination was capable of reducing the serum level of HIV p24 antigen and it was tolerated by the patients. Further studies are required to evaluate the clinical implications of these observations.
Orholm
M
M
Department of Infectious Diseases, University of Copenhagen, Hvidovre Hospital, Denmark.
Pedersen
C
C
Mathiesen
L
L
Dowd
P
P
Nielsen
J O
JO
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000276:immunology; D000328:Adult; D000368:Aged; D004359:Drug Therapy, Combination; D005260:Female; D015488:HIV Antigens / Q000032:analysis*; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage*; D008297:Male; D010865:Pilot Projects; D015215:Zidovudine / Q000008:administration & dosage*
D015488:HIV Antigens; D007370:Interferon Type I; D015215:Zidovudine